Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium.

SEQC/MAQC-III Consortium.

Nat Biotechnol. 2014 Sep;32(9):903-14. doi: 10.1038/nbt.2957. Epub 2014 Aug 24.

2.

Of text and gene--using text mining methods to uncover hidden knowledge in toxicogenomics.

Lee M, Liu Z, Kelly R, Tong W.

BMC Syst Biol. 2014 Aug 13;8:93. doi: 10.1186/s12918-014-0093-3.

3.

A phenome-guided drug repositioning through a latent variable model.

Bisgin H, Liu Z, Fang H, Kelly R, Xu X, Tong W.

BMC Bioinformatics. 2014 Aug 8;15:267. doi: 10.1186/1471-2105-15-267.

4.

A systems approach for analysis of high content screening assay data with topic modeling.

Bisgin H, Chen M, Wang Y, Kelly R, Fang H, Xu X, Tong W.

BMC Bioinformatics. 2013;14 Suppl 14:S11. doi: 10.1186/1471-2105-14-S14-S11. Epub 2013 Oct 9.

5.

Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.

Chen M, Hong H, Fang H, Kelly R, Zhou G, Borlak J, Tong W.

Toxicol Sci. 2013 Nov;136(1):242-9. doi: 10.1093/toxsci/kft189. Epub 2013 Aug 31.

PMID:
23997115
6.

A unifying ontology to integrate histological and clinical observations for drug-induced liver injury.

Wang Y, Lin Z, Liu Z, Harris S, Kelly R, Zhang J, Ge W, Chen M, Borlak J, Tong W.

Am J Pathol. 2013 Apr;182(4):1180-7. doi: 10.1016/j.ajpath.2012.12.033. Epub 2013 Feb 8.

PMID:
23395088
7.

SNPTrackâ„¢ : an integrated bioinformatics system for genetic association studies.

Xu J, Kelly R, Zhou G, Turner SA, Ding D, Harris SC, Hong H, Fang H, Tong W.

Hum Genomics. 2012 Jul 5;6:5. doi: 10.1186/1479-7364-6-5.

8.

Investigating drug repositioning opportunities in FDA drug labels through topic modeling.

Bisgin H, Liu Z, Kelly R, Fang H, Xu X, Tong W.

BMC Bioinformatics. 2012;13 Suppl 15:S6. doi: 10.1186/1471-2105-13-S15-S6. Epub 2012 Sep 11.

9.

In silico drug repositioning: what we need to know.

Liu Z, Fang H, Reagan K, Xu X, Mendrick DL, Slikker W Jr, Tong W.

Drug Discov Today. 2013 Feb;18(3-4):110-5. doi: 10.1016/j.drudis.2012.08.005. Epub 2012 Aug 28.

PMID:
22935104
10.

atBioNet--an integrated network analysis tool for genomics and biomarker discovery.

Ding Y, Chen M, Liu Z, Ding D, Ye Y, Zhang M, Kelly R, Guo L, Su Z, Harris SC, Qian F, Ge W, Fang H, Xu X, Tong W.

BMC Genomics. 2012 Jul 20;13:325. doi: 10.1186/1471-2164-13-325.

11.

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.

PLoS Comput Biol. 2011 Dec;7(12):e1002310. doi: 10.1371/journal.pcbi.1002310. Epub 2011 Dec 15.

12.
13.

Comparative analysis of predictive models for nongenotoxic hepatocarcinogenicity using both toxicogenomics and quantitative structure-activity relationships.

Liu Z, Kelly R, Fang H, Ding D, Tong W.

Chem Res Toxicol. 2011 Jul 18;24(7):1062-70. doi: 10.1021/tx2000637. Epub 2011 Jun 20.

PMID:
21627106
14.

Hypertrophy-associated polymorphisms ascertained in a founder cohort applied to heart failure risk and mortality.

Parsa A, Chang YP, Kelly RJ, Corretti MC, Ryan KA, Robinson SW, Gottlieb SS, Kardia SL, Shuldiner AR, Liggett SB.

Clin Transl Sci. 2011 Feb;4(1):17-23. doi: 10.1111/j.1752-8062.2010.00251.x.

15.

Providing context and interpretability to genetic association analysis results using the KGraph.

Kelly RJ, Smith JA, Kardia SL.

Adv Genet. 2010;72:181-93. doi: 10.1016/B978-0-12-380862-2.00008-4.

PMID:
21029853
16.

ArrayTrack: a free FDA bioinformatics tool to support emerging biomedical research--an update.

Xu J, Kelly R, Fang H, Tong W.

Hum Genomics. 2010 Aug;4(6):428-34. Review.

17.

Clinical and genetic modifiers of long-term survival in heart failure.

Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, Kardia SL, Dorn GW 2nd.

J Am Coll Cardiol. 2009 Jul 28;54(5):432-44. doi: 10.1016/j.jacc.2009.05.009.

18.

Complexity in the genetic architecture of leukoaraiosis in hypertensive sibships from the GENOA Study.

Smith JA, Turner ST, Sun YV, Fornage M, Kelly RJ, Mosley TH, Jack CR, Kullo IJ, Kardia SL.

BMC Med Genomics. 2009 Apr 7;2:16. doi: 10.1186/1755-8794-2-16.

19.

Multiple interactions between the alpha 2C- and beta1-adrenergic receptors influence heart failure survival.

Kardia SL, Kelly RJ, Keddache MA, Aronow BJ, Grabowski GA, Hahn HS, Case KL, Wagoner LE, Dorn GW 2nd, Liggett SB.

BMC Med Genet. 2008 Oct 23;9:93. doi: 10.1186/1471-2350-9-93.

20.

A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure.

Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, Diwan A, Martini JS, Sparks L, Parekh RR, Spertus JA, Koch WJ, Kardia SL, Dorn GW 2nd.

Nat Med. 2008 May;14(5):510-7. doi: 10.1038/nm1750. Epub 2008 Apr 20.

Supplemental Content

Loading ...
Support Center